Joy Yan, M.D., Ph.D., has served as Ambrx’s Chief Medical Officer since 2020. She is an oncology physician-scientist and executive with extensive experience in early and late clinical development. She has led the successful development of multiple oncology products from strategic planning through global submissions and approvals, including BMS’ first FDA Pilot Programs (RTOR, Project ORBIS, AAid) for nivolumab and ipilimumab. She also has broad clinical development experience at Janssen and Bayer, where she led Phase I, II and III studies exploring a variety of MOAs and evaluated NMEs (daratumumab, radium-223, anti-IL3R, ADCs, Bi-specifics, TKIs) across multiple tumor types. She has been successful in gaining FDA Fast Track Designation, Breakthrough Therapy Designation, Accelerated Approval, Priority Review, and Orphan Drug Designation for multiple programs with different tumor indications.
Dr. Yan completed her Ph.D. in Biochemistry & Molecular Biology at Johns Hopkins University. She received her M.D. from China Medical University and completed her residency and clinical fellowship at University of Washington.